Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Bullous Pemphigoid
NCT00286325Phase 2Completed
- Sponsor
- Duke University
- Start
- Mar 2005
- Primary completion
- Mar 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in Bullous Pemphigoid (BP), sponsored by Duke University. Started Mar 2005; status: completed.
02
Drugs
rituximab
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on NCT00286325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00286325.